PRAS40 Is an Integral Regulatory Component of Erythropoietin mTOR Signaling and Cytoprotection

Emerging strategies that center upon the mammalian target of rapamycin (mTOR) signaling for neurodegenerative disorders may bring effective treatment for a number of difficult disease entities. Here we show that erythropoietin (EPO), a novel agent for nervous system disorders, prevents apoptotic SH-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Zhao Zhong, Shang, Yan Chen, Wang, Shaohui, Maiese, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445503/
https://www.ncbi.nlm.nih.gov/pubmed/23029019
http://dx.doi.org/10.1371/journal.pone.0045456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445503/
https://www.ncbi.nlm.nih.gov/pubmed/23029019
http://dx.doi.org/10.1371/journal.pone.0045456

Ejemplares similares